These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 444361)

  • 1. Plasma half-life of clofibric acid in renal failure.
    Faed EM; McQueen EG
    Br J Clin Pharmacol; 1979 Apr; 7(4):407-10. PubMed ID: 444361
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 3. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug elimination by hemofiltration.
    Rumpf KW; Rieger J; Doht B; Ansorg R; Scheler F
    J Dial; 1977; 1(7):677-8. PubMed ID: 608876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
    Taylor T; Chasseaud LF
    J Pharm Sci; 1977 Nov; 66(11):1638-9. PubMed ID: 915750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacodynamics of practolol in chronic renal failure.
    Eastwood JB; Curtis JR; Smith RB
    Br Med J; 1973 Nov; 4(5888):320-2. PubMed ID: 4758423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin half-life in normal and impaired renal function.
    Perry PJ; Herron GR; King JC
    Clin Pharmacol Ther; 1974 Sep; 16(3):514-9. PubMed ID: 4413659
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
    Merk W; Graben N; Hartmann H; Nikolaus C; Schlierf G; Schwandt P
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):59-62. PubMed ID: 3557732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers.
    Harvengt C; Desager JP
    Int J Clin Pharmacol Biopharm; 1977 Jan; 15(1):1-4. PubMed ID: 576423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged serum half-life of cortisol in renal failure.
    Bacon GE; Kenny FM; Murdaugh HV; Richards C
    Johns Hopkins Med J; 1973 Feb; 132(2):127-31. PubMed ID: 4684170
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacokinetics of ceftazidime in healthy and renal failure subjects].
    Leroy A; Fillastre JP; Humbert G; Borsa F; Leguy F; Spencer GR
    Presse Med; 1988 Oct; 17(37):1917-20. PubMed ID: 2973585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofibrate and enzymatic induction in man.
    Houin G; Tillement JP
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):150-4. PubMed ID: 649234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic clofibrate therapy in maintenance hemodialysis patients.
    Sherrard DJ; Goldberg AB; Haas LB; Brunzell JD
    Nephron; 1980; 25(5):219-21. PubMed ID: 7383233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of clofibric acid (CPIB) metabolites in plasma of patients on clofibrate therapy.
    Faed EM; McQueen EG
    Clin Exp Pharmacol Physiol; 1979; 6(3):267-73. PubMed ID: 466868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of metoprolol and its metabolites in dialysis patients.
    Seiler KU; Schuster KJ; Meyer GJ; Niedermayer W; Wassermann O
    Clin Pharmacokinet; 1980; 5(2):192-8. PubMed ID: 7363534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma half-life of DDAVP in uraemic patients.
    Aunsholt NA; Vilhardt H; Schmidt EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):332-3. PubMed ID: 3799211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.